In CT26 murine models, monotherapy with the TLR7 agonist DSP-0509 achieved approximately 60% tumor growth inhibition (TGI), whereas combination therapy with anti-PD-1 antibodies enhanced TGI to >80%. The gene discussed is PDCD1; the disease is neoplasm.